Cytomed Therapeutics Limited (GDTC) Stock Price, Quote & News

Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a plu...

Industry: Biotechnology

Sector: Healthcare

Phone: 65 6250 7738

Website: w2.cytomed.sg

Address:

1 Commonwealth Lane, No. 08-22, Singapore, Singapore

BillionerOfKing Jan. 23 at 9:08 PM

$GDTC Current Stock Price: $1.00

0 · Reply

shameeza Jan. 14 at 7:51 PM

$GDTC what’s going on here?

0 · Reply

UgoGreg Jan. 14 at 7:15 PM

$GDTC https://youtu.be/pXFO9_cJJUM

0 · Reply

ForeverFund Dec. 24 at 11:01 AM

$GDTC The longer-term setup revolves around whether progress validates the underlying thesis beyond narrative appeal. Clear inflection points are required to justify renewed interest.

0 · Reply

Bennynito Dec. 11 at 1:05 PM

$GDTC $GEMI $GLXG $SMX $YQ newsworthy- we will allow it

0 · Reply

topstockalerts Dec. 11 at 1:02 PM

Pre Market Top Gainers PT2 $SMX $YQ $GDTC $GEMI $GLXG

0 · Reply

topstockalerts Dec. 11 at 12:20 PM

Pre Market Top Gainers PT2 $VSME $YQ $WOK $GEMI $GDTC

0 · Reply

Stock_Catcher Dec. 8 at 2:43 PM

$GDTC thin

0 · Reply

Stock_Catcher Dec. 8 at 1:24 PM

$GDTC CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

0 · Reply

DARKP00L Dec. 8 at 1:11 PM

$GDTC 08:11 on Dec. 08 2025 CytoMed Therapeutics Enters MoU With Universiti Malaya Medical Centre To Establish Phase 1 Clinical Trial Site To Investigate Safety And Efficacy Of CTM-GDT for No-Option Cancer Patients #tradeideas

0 · Reply

CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript

Oct 2, 2025, 7:00 AM EDT - 4 months ago

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

Aug 28, 2025, 9:00 AM EDT - 5 months ago

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition

Aug 18, 2025, 9:00 PM EDT - 5 months ago

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

Jul 21, 2025, 10:01 AM EDT - 6 months ago

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

Apr 28, 2025, 4:05 PM EDT - 9 months ago

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

Feb 6, 2025, 7:20 AM EST - 1 year ago

CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

Jan 6, 2025, 11:10 AM EST - 1 year ago

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GOSS GOVX IMRN

Jul 17, 2024, 7:00 AM EDT - 1 year ago

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Mar 20, 2024, 8:30 AM EDT - 2 years ago

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

Mar 18, 2024, 6:00 AM EDT - 2 years ago

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

Mar 4, 2024, 5:00 AM EST - 2 years ago

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

Jan 29, 2024, 7:00 AM EST - 2 years ago

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Dec 5, 2023, 7:30 AM EST - 2 years ago

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

Nov 17, 2023, 9:21 AM EST - 2 years ago

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

Nov 14, 2023, 7:47 AM EST - 2 years ago

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Oct 24, 2023, 1:00 PM EDT - 2 years ago

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

Sep 1, 2023, 8:00 PM EDT - 2 years ago

CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch

Aug 29, 2023, 9:00 AM EDT - 2 years ago

CytoMed Expands Research Collaboration into China After Entering Into MOU

Aug 20, 2023, 3:50 AM EDT - 2 years ago

Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal

ARQT SMMT

Aug 17, 2023, 7:30 AM EDT - 2 years ago

CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit

Aug 15, 2023, 1:00 PM EDT - 2 years ago

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γD T In Vivo Persistency

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Jul 27, 2023, 9:00 AM EDT - 2 years ago

CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology

Jul 6, 2023, 7:00 AM EDT - 2 years ago

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

May 11, 2023, 9:00 AM EDT - 2 years ago

CytoMed Therapeutics to Ring Nasdaq Closing Bell

May 9, 2023, 10:07 AM EDT - 2 years ago

CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology

Apr 13, 2023, 8:00 PM EDT - 3 years ago

CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering

Apr 7, 2023, 5:30 AM EDT - 3 years ago

U.S. IPO Weekly Recap: Small Deals Drive Activity In The IPO Market's Short Week

ARBB ATMU GDHG GMM ISPR KVUE MGIH

Feb 3, 2023, 5:46 PM EST - 3 years ago

IPO Update: CytoMed Therapeutics Aims For $11 Million U.S. IPO

BillionerOfKing Jan. 23 at 9:08 PM

$GDTC Current Stock Price: $1.00

0 · Reply

shameeza Jan. 14 at 7:51 PM

$GDTC what’s going on here?

0 · Reply

UgoGreg Jan. 14 at 7:15 PM

$GDTC https://youtu.be/pXFO9_cJJUM

0 · Reply

ForeverFund Dec. 24 at 11:01 AM

$GDTC The longer-term setup revolves around whether progress validates the underlying thesis beyond narrative appeal. Clear inflection points are required to justify renewed interest.

0 · Reply

Bennynito Dec. 11 at 1:05 PM

$GDTC $GEMI $GLXG $SMX $YQ newsworthy- we will allow it

0 · Reply

topstockalerts Dec. 11 at 1:02 PM

Pre Market Top Gainers PT2 $SMX $YQ $GDTC $GEMI $GLXG

0 · Reply

topstockalerts Dec. 11 at 12:20 PM

Pre Market Top Gainers PT2 $VSME $YQ $WOK $GEMI $GDTC

0 · Reply

Stock_Catcher Dec. 8 at 2:43 PM

$GDTC thin

0 · Reply

Stock_Catcher Dec. 8 at 1:24 PM

0 · Reply

DARKP00L Dec. 8 at 1:11 PM

0 · Reply

DARKP00L Dec. 8 at 1:08 PM

$GDTC 08:08 on Dec. 08 2025 CytoMed Therapeutics Enters Into MOU With UMMC To Establish Phase I Clinical Trial To Investigate Safety And Efficacy Of CytoMed's Patented Allogeneic Unmodified Gamma Delta T Cells For No-Option Cancer Patients In Malaysia #tradeideas

0 · Reply

topstockalerts Dec. 4 at 1:56 PM

Pre Market Top Gainers PT2 $FLYE $JXG $VTGN $GDTC $COOT

0 · Reply

topstockalerts Dec. 4 at 1:01 PM

Pre Market Top Gainers PT2 $CBIO $JXG $COOT $CLNN $GDTC

0 · Reply

topstockalerts Dec. 4 at 12:19 PM

Pre Market Top Gainers PT2 $CVKD $BRR $CLNN $SUGP $GDTC

0 · Reply

Panama73 Nov. 18 at 6:04 PM

$LFS $EPSM $BTQ $GDTC

0 · Reply

amara_solomon39 Nov. 18 at 4:56 PM

$GDTC I’m telling you - NXXT is coiling like a SPRING LOADED GRENADE. Break $1.50 and this mf AIRSTRIKES to $3+. PT $7 after rerate. I’m trading my setup - you trade yours.

0 · Reply

Panama73 Nov. 18 at 4:11 PM

$GDTC Chairman's effective holdings 21.95%.

0 · Reply

DaBullRunner Nov. 18 at 1:12 PM

$GDTC watching 🚨COSM🚨 adding off that solid news 🚢📦📦📦 I’m even willing to put some of my COIN TSLA profits into COSM👇💰💰💰

0 · Reply

DaBullRunner Nov. 18 at 1:11 PM

$GDTC watching… 🚨COSM🚨 adding off that solid news 🚢📦📦📦 I’m even willing to put some of my COIN TSLA profits into COSM👇💰💰💰

0 · Reply

PUMPIT613 Nov. 6 at 3:19 PM

$GDTC

0 · Reply

Market Cap	10.94M
Revenue (ttm)	50,000.00
Net Income (ttm)	-1.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,680.00%
Debt to Equity Ratio	0.06

Volume	10,100
Avg Vol	51,226
Day's Range	N/A - N/A
Shares Out	10.94M
Stochastic %K	26%
Beta	-0.16
Analysts	Strong Buy
Price Target	$5.00